AOD 9604 + Semaglutide (advanced) For aggressive fat loss, combining appetite suppression with enhanced fat oxidation can be extremely effective
Sack MN, Fyhrquist FY, Saijonmaa OJ, Fuster V, Kovacic JC
The neuroprotective effects align with BDNF-supporting mechanisms, including reduced hippocampal lipid peroxidation
Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )